Patriot in Patches? Yvette Cleland's Big Pharma Bonanza Fuels Far-Right Facade

Yvette Cleland struts across X as a fierce defender of "British values," decrying "mass uncontrolled immigration," "woke nonsense," and the "rubbing of noses in diversity" that she claims has gutted the UK. Her @itsonlyYC feed, with its endless tirades against multiculturalism and globalist "cretinati," paints her as a Boudicca reborn—fighting for a "high trust, low crime society" overrun by foreigners and ECHR-enabled rapists. Yet scratch the surface, and the armor cracks: Cleland's empire, CPL Life Sciences, is a global staffing juggernaut bankrolled by the very Big Pharma behemoths she's indirectly tied to through opioids, vaccines, and unchecked corporate globalization. Her "patriotic" pivot? A cynical rebrand, funded by the diversity-drenched, border-blind industry she now rails against. This is the ammo: a woman whose fortune flows from international talent pipelines and DEI accolades, now peddling isolationism to the dispossessed she helped displace.

The Pharma Payday: Opioids, Vaccines, and a CEO's Seven-Figure Gravy Train

Cleland didn't stumble into politics from a factory floor; she clawed her way up Big Pharma's ladder, launching fentanyl patches at Janssen (Johnson & Johnson) in the 1990s before co-founding Clinical Professionals—now CPL Life Sciences—in 2004. As CEO since 2018, she oversees a firm that staffs clinical trials, regulatory roles, and R&D for pharma titans like Pfizer, AstraZeneca, and GSK—companies raking in billions from opioids and COVID jabs while facing lawsuits for addiction epidemics and rushed rollouts. CPL doesn't brew the drugs, but it oils the machine: placing temps for vaccine scale-ups that Cleland herself hyped as "regulatory opportunities" in 2022 reports, amid a sector boom that swelled CPL's parent, CPL Resources, to record revenues ahead of a Bain Capital buyout.

No public filings spill Cleland's exact paycheck—UK Companies House tracks related entities with group revenues in the tens of millions—but as head of a division placing talent across Europe and North America, her stake is fat. This isn't scrappy entrepreneurship; it's elite extraction from an industry that peddled fentanyl as "pain control innovation" (her words in a 2023 podcast) while overdose deaths hit 72,776 from fentanyl in the US in 2023. Now, she funnels that cash into GB PAC and Advance UK, a "patriotic" splinter bankrolled by ex-UKIP hardliners—ironic for a woman whose firm thrived on the global labor flows she decries as "demographic change with no consultation."

DEI Darling or Diversity Destroyer? Cleland's Award-Winning Hypocrisy

Cleland's CPL is a poster child for the "woke" corporate playbook she savages online. The firm boasts "a strong history of excellent female leaders" and a DE&I strategy "designed to incrementally reduce inequality," earning ESG Awards for Diversity, Equality & Inclusion in 2022. Partnerships with the Irish Centre for Diversity? Check. Surveys on ethnic pay gaps? Mandatory. "Diversity is pivotal to our success," CPL preaches, recruiting "across Europe" for biotech's "global talent needs." Yet on X, Cleland torches this as societal poison: "You rubbed our noses in diversity... 95% [migrants] a net drain," she fumed in August 2025, blasting TV ads as "way over representative" of ethnic minorities.

Her feed is a DEI demolition derby: "Woke mind virus and cultural Marxism" breeds "loathsome creatures," she rants, while grooming gangs get a pass for "diversity's sake." Oxford's fall from top unis? "Price you pay for DEI schemes." Multiculturalism? "Failed... little white girls getting groomed." But when CPL wins DEI plaudits, it's "pivotal to success." Cleland's not just hypocritical—she's cashing checks from the inclusion industrial complex she condemns, staffing diverse teams for pharma's borderless labs while her PAC pushes ECHR exits to "protect citizens" from the migrants her firm helps import.

Globalist Goldmine, Nationalist Noise: The Borderless Business of a "Britain First" Booster

CPL's "international pharmaceutical recruitment" spans continents, feeding "global life sciences organizations" with talent for "efficient, resilient" supply chains—precisely the globalization Cleland lambasts as "obliteration of our culture." She decries low-skilled migrants as "95% net drain," yet her firm imports skilled ones for Pfizer's opioid ops and AstraZeneca's vaccine rushes—clients entangled in multi-billion-dollar settlements for deceptive marketing. "Train our own 9 million economically inactive," she demands on X, ignoring CPL's role in offshoring talent pools.

This isn't coincidence; it's contradiction. Cleland's Janssen fentanyl days globalized pain relief (and addiction), her CPL era globalized staffing—yet now, as GB PAC's Regional Director, she backs Advance UK's "economic nationalism" and border walls. Her "Boudiccas Daughters" VAWG fight? Noble, until twisted into anti-migrant screeds: "Enough... we are full, crime ridden & poorer." The cash? No direct donation trails, but her pharma-forged wealth props up a PAC labeled "far-right threat" by watchdogs—funding the fury she profits from stoking.

Yvette Cleland isn't a patriot; she's a pharma phoenix, reborn in right-wing rags from the ashes of the globalism she peddled. Her ties aren't lies—they're ledgers: millions from migrant-staffed labs, DEI awards she disowns, opioid echoes she romanticizes. Britain’s real threat? Grifters like her, preaching sovereignty while pocketing the proceeds of the system they sabotage. Time to call the bluff: Follow the fentanyl to the funding, and watch the "Great British" facade crumble.